Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

SLI-381 (Adderall XR).

Kate McKeage1, Lesley J Scott

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

CNS Drugs
|June 28, 2003
PubMed
Summary

SLI-381, an extended-release ADHD medication, significantly improved behavior in children compared to placebo. This new formulation offers sustained symptom control throughout the day.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2022
Same author

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2021
Same author

Opicapone: A Review in Parkinson's Disease.

CNS drugs·2021
Same author

Lumasiran: First Approval.

Drugs·2021
Same author

Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2020
Same author

Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2020

Area of Science:

  • Pharmacology
  • Neuroscience
  • Pediatrics

Background:

  • Attention-deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder.
  • Current ADHD treatments include stimulant medications, often requiring multiple daily doses.
  • Extended-release formulations aim to improve treatment adherence and efficacy.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of SLI-381, an extended-release amphetamine formulation, in children with ADHD.
  • To assess the dose-response relationship of SLI-381.
  • To compare the effectiveness of SLI-381 with placebo in improving behavioral symptoms.

Main Methods:

  • A 3-week, double-blind, randomized, placebo-controlled study.
  • 563 children diagnosed with ADHD participated.
  • SLI-381 was administered once daily at doses of 10, 20, or 30 mg.
  • Behavioral outcomes were assessed using the Connors Global Index Scale for teachers (CGIS-T).

Main Results:

  • SLI-381 significantly improved morning and afternoon behavior scores compared to placebo (p < 0.001).
  • A dose-response relationship was observed, with higher doses leading to greater improvements.
  • Behavioral scores after SLI-381 treatment were comparable to those of children without ADHD.
  • Parental ratings indicated sustained symptom control throughout the day.

Conclusions:

  • SLI-381 is an effective and well-tolerated extended-release formulation for managing ADHD symptoms in children.
  • Once-daily administration of SLI-381 provides sustained behavioral improvement.
  • The study supports SLI-381 as a viable treatment option for pediatric ADHD.

Related Experiment Videos